BIVI Announces Prascend¨ Horse Owner Contest Winners
Barn Buzz Testimonial Contest Ends – Four Winners Selected

ST. JOSEPH, Mo. (Sept. 24, 2014) – Prascend¨ (pergolide mesylate) has been available to U.S. veterinarians and horse owners for nearly three years as a treatment option for horses suffering from Pituitary Pars Intermedia Dysfunction (PPID), formerly known as equine Cushing’s disease. In an effort to raise awareness of the disease and share treatment success stories, Boehringer Ingelheim Vetmedica, Inc. (BIVI), manufacturers of PRASCEND, recently hosted a testimonial contest.

“The contest was designed to help us not only capture PRASCEND treatment success stories but also increase horse-owner awareness of the disease and its early clinical signs,” says Dwana Neal, brand manager, equine pharmaceuticals, BIVI. “Since PRASCEND was launched, we have received a number of success stories anecdotally, but through the contest we were not only able to draw attention to the disease, but also get a real sense of the impact PRASCEND has made for horses and owners dealing with this debilitating disease.”

The Barn Buzz Testimonial Contest was targeted to owners of horses diagnosed with PPID that had successful treatment results with PRASCEND. Horse owners visited a website and submitted their success stories for a chance to win prizes. One grand prize winner and three runners-up were selected from the entries. Winners were chosen based on the evaluation of written history, along with before and after photos